Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9851568 | 0.88 | PKM (0.63) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL243095 | 0.87 | PKM (0.54) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL10790081 | 0.86 | PKM (0.50) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL5900909 | 0.84 | PKM (0.51) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL16014031 | 0.83 | TSHR (0.50) | HTTALDH1A1POLBTSHRLMNA | |
| SCHEMBL13324056 | 0.83 | PKM (0.51) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL6935661 | 0.83 | ALDH1A1 (0.54) | PKMALDH1A1POLBMEN1KMT2A | |
| SCHEMBL16572126 | 0.81 | PKM (0.56) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL14149366 | 0.81 | PKM (0.59) | PKMHTTALDH1A1POLBMEN1 | |
| SCHEMBL825108 | 0.80 | PKM (0.63) | PKMHTTALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751467-A | Preparation method of 2-oxa-6-aza-spiro [3,3] heptane | 安徽乐雍生物科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-111819176-B | 4-azaindole compounds | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| EP-3728252-B1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-27 | — | — | US | disclosed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011140936-A1 | 5,5-DISUBSTITUTED-2-IMINO-PYRROLIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | 上海恒瑞医药有限公司 (CN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011059839-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010141817-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| EP-0114079-B1 | ARYLSULPHONYL AZETIDINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS INTERMEDIATES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-09-16 | — | — | EP | disclosed |
| US-4591457-A | Arysulphonyl azetidine compounds used as intermediates | SHELL OIL COMPANY (US) | 1986-05-27 | — | — | US | disclosed |
| US-4569795-A | Arylsulphonyl azetidine compounds, their preparation and their use as intermediates | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0114079-A1 | Arylsulphonyl azetidine compounds, their preparation and their use as intermediates | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | PKM 4720/4885HTT 4393/4885ALDH1A1 1039/4885 |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | PKM 4720/4885HTT 4393/4885ALDH1A1 1039/4885 |
| US-11964949-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | PKM 733/4885HTT 4523/4885ALDH1A1 1310/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | PKM 521/4885HTT 814/4885ALDH1A1 728/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | PKM 2092/4885HTT 287/4885ALDH1A1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.